Elsewhere in the market, US-based pharmaceutical company AbbVie has reported that its Phase III TEMPO-2 trial of tavapadon has met its primary endpoints. "UCB drops Parkinson’s treatment after ...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see United Community Banks, Inc. (NYSE:UCB) is about to trade ex-dividend in the next 4 days. The ...

The new drug joins UCB’s recently FDA-approved FcRn-targeting antibody Rystiggo (rozanolixizumab), which got the nod from the US regulator in June for gMG patients who are either AChR or anti ...

UCB’s Bimzelx is firmly on physicians’ radars ... I think on itch, ... really gives us a very compelling dataset. And, given the long history of safety with Cosentyx, we think a very ...

The US FDA has approved a supplemental new drug application (sNDA) for UCB's Vimpat (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 ...

United Community Banks ( NYSE:UCB ) Full Year 2024 Results Key Financial Results Revenue: US$901.2m (up 12% from FY... United Community Banks, Inc. ( NYSE:UCB ) will pay a dividend of $0.24 on the ...

United Community Banks has shown improvement in deposits, loans, and income, leading to an upgrade from 'sell' to a soft ...

United Commercial Bank (UCB) PLC has recorded a remarkable net deposit growth exceeding Tk 1,332 crore in February 2025. This achievement, realised in just 20 working days, underscores the renewed ...